A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit.
The selloff came as investors repriced risk across equities amid fears of persistently higher rates, sparked by soft demand at the 20-year Treasury auction.
Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Hims & Hers Health (NYSE:HIMS) and its peers.
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers.
HIMS & HERS HEALTH (NYSE:HIMS) meets Minervini’s Trend Template with strong technicals and explosive earnings growth, making it a high-growth momentum candidate.
The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact.
Short interest in Hims & Hers rose to a record high of 37%, continuing a four-week climb, even as the stock surged 42% last week. The company’s quarterly revenue more than doubled, surpassing analyst expectations.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
